High	O
MITF	O
Expression	O
Is	O
Associated	O
with	O
Super	O
-	O
Enhancers	O
and	O
Suppressed	O
by	O
CDK7	O
Inhibition	O
in	O
Melanoma	S-DISEASE
.	O
Cutaneous	B-DISEASE
melanoma	E-DISEASE
is	O
an	O
aggressive	O
tumor	S-DISEASE
that	O
accounts	O
for	O
most	O
skin	B-DISEASE
cancer	E-DISEASE
deaths	O
.	O


Among	O
the	O
physiological	O
barriers	O
against	O
therapeutic	O
success	O
is	O
a	O
strong	O
survival	O
program	O
driven	O
by	O
genes	O
such	O
as	O
MITF	O
that	O
specify	O
melanocyte	O
identity	O
,	O
a	O
phenomenon	O
known	O
in	O
melanoma	S-DISEASE
biology	O
as	O
lineage	O
dependency	O
.	O


MITF	O
overexpression	O
is	O
occasionally	O
explained	O
by	O
gene	O
amplification	O
,	O
but	O
here	O
we	O
show	O
that	O
super	O
-	O
enhancers	O
are	O
also	O
important	O
determinants	O
of	O
MITF	O
overexpression	O
in	O
some	O
melanoma	O
cell	O
lines	O
and	O
tumors	S-DISEASE
.	O


Although	O
compounds	O
that	O
directly	O
inhibit	O
MITF	O
are	O
unavailable	O
,	O
a	O
covalent	O
CDK7	O
inhibitor	O
,	O
THZ1	O
,	O
has	O
recently	O
been	O
shown	O
to	O
potently	O
suppress	O
the	O
growth	O
of	O
various	O
cancers	S-DISEASE
through	O
the	O
depletion	O
of	O
master	O
transcription	O
-	O
regulating	O
oncogenes	O
and	O
the	O
disruption	O
of	O
their	O
attendant	O
super	O
-	O
enhancers	O
.	O


We	O
also	O
show	O
that	O
melanoma	O
cells	O
are	O
highly	O
sensitive	O
to	O
CDK7	O
inhibition	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
that	O
THZ1	O
can	O
dismantle	O
the	O
super	O
-	O
enhancer	O
apparatus	O
at	O
MITF	O
and	O
SOX10	O
in	O
some	O
cell	O
lines	O
,	O
thereby	O
extinguishing	O
their	O
intracellular	O
levels	O
.	O


Our	O
results	O
show	O
a	O
dimension	O
to	O
MITF	O
regulation	O
in	O
melanoma	O
cells	O
and	O
point	O
to	O
CDK7	O
inhibition	O
as	O
a	O
potential	O
strategy	O
to	O
deprive	O
oncogenic	O
transcription	O
and	O
suppress	O
tumor	S-DISEASE
growth	O
in	O
melanoma	S-DISEASE
.	O
